2025-05-30 - Analysis Report
Okay, here's a comprehensive report on TG Therapeutics Inc. (TGTX) based on the provided data.

## TG Therapeutics Inc. (TGTX) Analysis

TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Relative Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 68.14%
*   **VOO Cumulative Return:** 82.09%
*   **Absolute Divergence:** -14.0 (TGTX underperformed VOO by 14.0%)
*   **Relative Divergence:** 19.9

**Analysis:** TGTX has underperformed the S&P 500. The relative divergence of 19.9 indicates that TGTX's current divergence is in the lower range of its historical divergence from VOO. This suggests that while it's currently underperforming, it's closer to its historical best relative performance than its worst.

**Alpha/Beta Analysis:**

| Year       | CAGR     | MDD  | Alpha   | Beta   | Cap(B) |
|------------|----------|------|---------|--------|--------|
| 2015-2017  | -6.0%    | 56.5% | -35.0%  | -0.1   | 1.3    |
| 2016-2018  | -8.0%    | 58.6% | -26.0%  | -0.0   | 0.7    |
| 2017-2019  | 74.0%    | 58.6% | 44.0%   | -0.0   | 1.8    |
| 2018-2020  | 402.0%   | 58.6% | 377.0%  | -0.1   | 8.3    |
| 2019-2021  | 125.0%   | 63.5% | 70.0%   | -0.2   | 3.0    |
| 2020-2022  | -76.0%   | 70.4% | -82.0%  | -0.3   | 1.9    |
| 2021-2023  | -350.0%  | 70.4% | -367.0% | -0.8   | 2.7    |
| 2022-2024  | 71.0%    | 73.1% | 54.0%   | -1.0   | 4.8    |
| 2023-2025  | 75.0%    | 73.1% | 45.0%   | 0.3    | 5.7    |

**Analysis:**

*   **CAGR:** Volatile, ranging from highly negative to extremely positive.
*   **MDD:**  High Maximum Drawdown (MDD) consistently, indicating significant risk.
*   **Alpha:**  Mixed, with periods of strong outperformance (positive Alpha) and significant underperformance (negative Alpha) relative to the S&P 500.
*   **Beta:** Generally low or negative, suggesting a weak correlation with the overall market. This could indicate the stock's price movements are more influenced by company-specific factors rather than broad market trends.
*   **Cap:** Market capitalization varies.

### 2. Recent Price Action

*   **Current Price:** $35.71
*   **Previous Close:** $35.14
*   **Change:** 1.62% (Positive movement)
*   **5-day Moving Average:** 34.98
*   **20-day Moving Average:** 35.648
*   **60-day Moving Average:** 38.077

**Analysis:** The stock is trading above its 5-day and 20-day moving averages, but below its 60-day moving average. The recent positive change of 1.62% indicates a short-term upward trend. The price increase may be due to recent news or events.

### 3. Market Risk Indicators and Outlook

*   **MRI:** 0.366 (Low Risk)
*   **RSI:** 61.18 (Approaching overbought territory)
*   **PPO:** 0.3805 (Positive momentum)
*   **Hybrid Signal:** Cash_3%_Buy 80% of cash (746 shares - Caution - MRI:0.37)
*   **Recent (20-day) Relative Divergence Change:** 0.2 (+) (Short-term increase)
*   **Expected Return:** -196.8% (Significant underperformance expected relative to S&P 500 over a long-term investment horizon)

**Analysis:**

*   The MRI indicates a low-risk environment, though the caution note in the Hybrid Signal is worth considering.
*   The RSI is approaching overbought levels, suggesting the recent upward momentum might be unsustainable in the short term.
*   The PPO indicates positive momentum.
*   The Hybrid Signal suggests a buy recommendation with caution, given the MRI.
*   The increasing relative divergence supports the short-term upward trend.
*   The significantly negative expected return (-196.8%) suggests a very bearish long-term outlook, with substantial underperformance relative to the S&P 500.

### 4. Recent News & Significant Events

*   **May 26, 2025:** Major business developments, regulatory changes, or market events.
*   **May 30, 2025:** Analyst discussions on recent performance and outlook.
*   **May 28, 2025:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **May 29, 2025:** Market experts highlight both risks and opportunities.

**Analysis:** Recent news indicates potential volatility and significant events influencing the stock. Investors should closely monitor company announcements and industry news.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-09 | 0.03  | 0.12 B$   |
| 2024-11-07 | 0.03  | 0.08 B$   |
| 2024-08-09 | 0.05  | 0.07 B$   |
| 2024-05-06 | -0.07 | 0.06 B$   |
| 2025-05-09 | -0.07 | 0.06 B$   |

**Analysis:** The company's EPS has fluctuated. Most recent quarters show positive EPS but history includes negative values. Revenue has been generally increasing. The upward trend in revenue is a positive sign.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.12B  | 87.14%        |
| 2024-12-31 | $0.11B  | 85.77%        |
| 2024-09-30 | $0.08B  | 88.86%        |
| 2024-06-30 | $0.07B  | 88.70%        |
| 2024-03-31 | $0.06B  | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE     |
|------------|---------|---------|
| 2025-03-31 | $0.24B  | 2.13%   |
| 2024-12-31 | $0.22B  | 10.49%  |
| 2024-09-30 | $0.19B  | 2.02%   |
| 2024-06-30 | $0.18B  | 3.87%   |
| 2024-03-31 | $0.16B  | -6.69%  |

**Analysis:**

*   **Revenue:** Shows a steady increase over the past year.
*   **Profit Margin:** Very high, indicating efficient cost management and potentially strong pricing power.
*   **Equity:** Increasing, suggesting positive capital accumulation.
*   **ROE:** Fluctuates, with some quarters showing strong returns and others being weaker. The recent ROE is positive but lower than the peak.

### 7. Overall Analysis and Recommendations

TG Therapeutics Inc. (TGTX) presents a mixed picture:

*   **Positives:** Recent positive price momentum, increasing revenue, high profit margins, and a low MRI. Hybrid signal recommends buying.
*   **Negatives:** Underperformance relative to the S&P 500, volatile historical performance, high MDD, approaching overbought RSI, and a significantly negative long-term expected return.

**Recommendations:**

*   **Short-Term:** The recent positive momentum suggests a possible short-term trading opportunity. However, the approaching overbought RSI indicates caution.
*   **Long-Term:** The negative expected return raises significant concerns about long-term investment. The volatile historical performance and high MDD suggest substantial risk.
*   **Due Diligence:** Given the conflicting signals, thorough due diligence is crucial. Investors should closely monitor company news, regulatory developments, and industry trends. Consider the company's pipeline and the potential for future revenue growth.

**In summary, TGTX appears to be a high-risk, potentially high-reward investment. Short-term trading opportunities might exist, but the long-term outlook is highly uncertain.**
